Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
To create leading company developing medicines targeting metalloenzymes
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
Blanda will be responsible for overseeing Evonik’s amino acids and functional feed additives business and the expansion of its precision livestock farming approach
Subscribe To Our Newsletter & Stay Updated
